By Colin Kellaher
Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer.
Bristol Myers on Friday said the approval covers the combination for the first-line treatment of adults with unresectable or advanced hepatocellular carcinoma.
Liver cancer is the third most frequent cause of cancer death worldwide, and hepatocellular carcinoma is the most common type of liver cancer, accounting for 90% of global cases, the Princeton, N.J., biopharmaceutical company said.
The Opdivo/Yervoy combination is already approved in several cancer indications worldwide. The U.S. Food and Drug Administration is reviewing the combination as a potential first-line treatment option for adults with unresectable hepatocellular carcinoma, with a target action date of April 21.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 07, 2025 07:12 ET (12:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。